Lenvatinib

Phase 2Active

0 views this week 0 watching💤 Quiet

Interest: 39/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Adenoid Cystic Carcinoma

Conditions

Adenoid Cystic Carcinoma

Trial Timeline

May 19, 2016 → May 1, 2026

NCT ID

NCT02780310

About Lenvatinib

Lenvatinib is a phase 2 stage product being developed by Eisai for Adenoid Cystic Carcinoma. The current trial status is active. This product is registered under clinical trial identifier NCT02780310. Target conditions include Adenoid Cystic Carcinoma.

What happened to similar drugs?

1 of 2 similar drugs in Adenoid Cystic Carcinoma were approved

Approved (1) Terminated (0) Active (1)

🔄Mometasone Furoate nasal spray + PlaceboOrganonPhase 3

✅mometasone furoate nasal sprayOrganonApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03533361	Pre-clinical	Completed	—	—	Thyroid Cancer
NCT02211222	Pre-clinical	Completed	—	Jun 1, 2015	Differentiated Thyroid Cancer
NCT05901194	Phase 1/2	Active	Jul 10, 2024	Apr 1, 2027	Hepatocellular Carcinoma Non-resectable
NCT06138769	Phase 2	Active	Jul 20, 2023	Nov 1, 2027	Hepatocellular Carcinoma
NCT05171335	Phase 2	Recruiting	Jun 20, 2022	Dec 30, 2027	Hepatocellular Carcinoma
NCT05103904	Phase 2	Recruiting	Apr 19, 2022	Nov 4, 2026	Recurrent Hepatocellular Carcinoma
NCT04321954	Phase 2	Active	Mar 9, 2021	May 27, 2026	Differentiated Thyroid Cancer
NCT04297254	Approved	Completed	Feb 4, 2021	Jul 31, 2023	Carcinoma, Hepatocellular
NCT04447755	Phase 2	Completed	Jul 30, 2020	Feb 13, 2025	Relapsed or Refractory Solid Tumors
NCT04008082	Pre-clinical	Completed	May 14, 2019	Jan 28, 2022	Carcinoma, Hepatocellular
NCT03506048	Phase 2	Terminated	Jan 16, 2019	Jun 24, 2021	Differentiated Thyroid Gland Carcinoma
NCT03009292	Phase 1	Completed	Aug 6, 2018	Aug 27, 2021	Solid Tumor
NCT03663114	Pre-clinical	Completed	Jul 2, 2018	Feb 20, 2020	Carcinoma, Hepatocellular
NCT02846766	Phase 2	Withdrawn	Jul 1, 2018	Jun 1, 2021	Cancer
NCT03433703	Phase 2	Terminated	Apr 26, 2018	Jan 7, 2019	Carcinoma, Hepatocellular
NCT03573960	Approved	Completed	Apr 1, 2018	Sep 4, 2025	Thyroid Neoplasms
NCT03168074	Phase 2	UNKNOWN	Mar 28, 2017	Mar 28, 2021	Breast Cancer
NCT02953743	Phase 1	Completed	Sep 1, 2016	Dec 28, 2020	Unresectable Hepatocellular Carcinoma (HCC)
NCT02780310	Phase 2	Active	May 19, 2016	May 1, 2026	Adenoid Cystic Carcinoma
NCT02579616	Phase 2	Completed	Oct 23, 2015	Feb 27, 2019	Biliary Tract Cancer

Competing Products

11 competing products in Adenoid Cystic Carcinoma

See all competitors

Product	Company	Stage	Hype Score
Enfortumab Vedotin	Astellas Pharma	Phase 2	42
Lenvatinib + Pembrolizumab	Eisai	Phase 2	39
P-Sam	AstraZeneca	Phase 2	42
Cetuximab	Merck	Phase 1/2	28
Pembrolizumab	Merck	Phase 2	35
Dovitinib	Novartis	Phase 2	35
Dovitinib (TKI258)	Novartis	Phase 2	35
AG-013736 (AXITINIB)	Pfizer	Phase 2	35
Regorafenib	Bayer	Phase 2	32
Mometasone Furoate nasal spray + Placebo	Organon	Phase 3	34
mometasone furoate nasal spray	Organon	Approved	37